Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 13;7(2):e006949. doi: 10.1161/JAHA.117.006949

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Pretreatment of eMSCs with CD73 inhibitor, APCP, does not decrease cell viability following implantation onto MI/R injured myocardium. Live/dead fluorescent imaging of eMSCs explanted from MI/R injured hearts after (A) 1 day without APCP pretreatment, (B) 1 day with APCP pretreatment, (C) 3 days without APCP pretreatment, and (D) 3 days with APCP pretreatment. E, Viability was not statistically different between eMSCs with our without APCP pretreatment at days 1 or 3. Data are expressed as mean±SEM, n=6. Unpaired t test. APCP indicates α,β‐methylene adenosine diphosphate; eMSCs, encapsulated mesenchymal stromal cells; MI/R, myocardial ischemia/reperfusion.